More than 40,000 healthcare workers from across the world are reportedly taking part in a global trial of two anti-malarial drugs – hydroxychloroquine and chloroquine – to check their effectiveness in preventing the COVID-19 infection, with the first tests having begun in the UK cities of Brighton and Oxford.
The World Health Organisation (WHO) is putting its coronavirus treatment trial of hydroxychloroquine on pause to review its benefits and harmful effects, WHO Director-General Tedros Adhanom Ghebreyesus said Monday.
According to the director-general, the data is being reviewed by the Data Safety Monitoring Board.
The statement comes after the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU) said in a press release on 21 May that it has started a research project dubbed COPCOV in cooperation with the University of Oxford and the Wellcome charity organisation. The research involves 40,000 frontline health workers and staff from Europe, Africa, Asia, and South America who have close contact with coronavirus-infected patients to determine definitively if chloroquine and hydroxychloroquine are effective in preventing COVID-19.
Hydroxychloroquine has been considered effective in treating COVID-19 when combined with zinc and azithromycin by some of the world’s leading epidemiologists. At the same time, the US Food and Drug Administration (FDA) has warned of the danger of side effects of these antimalarial drugs when treating the disease.
World May See Second Peak of Current Wave of COVID-19 Before Second Wave
In the meantime, Executive Director of the World Health Organisation’s Health Emergencies Programme Michael J. Ryan said that the world may experience a second peak of the current COVID-19 wave.
The World Health Organisation declared the COVID-19 outbreak a pandemic on 11 March. To date, more than 5.4 million people have been infected with the coronavirus worldwide, with over 345,000 fatalities, according to Johns Hopkins University.
Sourse: sputniknews.com
